CSL (OTCMKTS:CSLLY) Hits New 52-Week Low After Analyst Downgrade

CSL Limited Sponsored ADR (OTCMKTS:CSLLY)’s share price reached a new 52-week low during mid-day trading on Thursday after Royal Bank Of Canada downgraded the stock from a moderate buy rating to a hold rating. The company traded as low as $52.00 and last traded at $54.0950, with a volume of 6737 shares trading hands. The stock had previously closed at $56.82.

A number of other equities research analysts also recently issued reports on the company. Canaccord Genuity Group upgraded CSL from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, October 28th. Zacks Research raised CSL from a “strong sell” rating to a “hold” rating in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, CSL has a consensus rating of “Moderate Buy”.

CSL Price Performance

The company has a debt-to-equity ratio of 0.50, a current ratio of 2.46 and a quick ratio of 1.12. The company has a 50-day moving average price of $59.98 and a 200 day moving average price of $65.73.

About CSL

CSL Limited (OTCMKTS: CSLLY) is a global biotechnology company headquartered in Melbourne, Australia that develops, manufactures and delivers a range of plasma-derived and recombinant therapeutics, vaccines and related services. Its principal businesses include CSL Behring, which focuses on specialty biotherapies for bleeding disorders, immune deficiencies, hereditary angioedema and other serious conditions; Seqirus, an influenza vaccine company formed following CSL’s acquisition of Novartis’ influenza vaccine business; and CSL Plasma, a network of plasma collection centers that supplies the raw material for many of its therapies.

The company’s product portfolio spans immunoglobulins, clotting factor concentrates, albumin and other protein-based treatments used in the management of chronic and acute rare diseases, as well as seasonal and pandemic influenza vaccines.